FIELD: medicine.
SUBSTANCE: invention relates to polypeptides which are covalently bonded to molecular scaffolds so that two or more peptide loops are closed between points of attachment to the scaffold. In particular, the invention describes peptides which bind with high affinity to type 1 membrane metalloprotease (MT1-MMP). Invention also describes drug conjugates containing said peptides conjugated with one or more effector and/or functional groups, which are used in imaging and targeted therapy of cancer.
EFFECT: bicyclic peptide ligands specific for MT1-MMP are disclosed.
30 cl, 13 dwg, 17 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | 2015 |
|
RU2708459C2 |
| NOVEL POLYPEPTIDES | 2014 |
|
RU2674604C2 |
| MODULATING THE SPECIFICITY OF STRUCTURED PROTEINS | 2012 |
|
RU2745572C2 |
| PEPTIDES OR THEIR PHARMACEUTICALLY ACCEPTABLE ACIDS OR SALTS, PHARMACEUTICAL COMPOSITION SHOWING ANTAGONISTIC ACTIVITY WITH RESPECT TO BOMBESINE, METHOD OF TREATMENT OF MAMMALIAN WITH CANCER | 1994 |
|
RU2114118C1 |
| POLY-LIGAND MEDICINAL CONJUGATES AND USE THEREOF | 2016 |
|
RU2722449C2 |
| GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | 2011 |
|
RU2604067C2 |
| MODULATION OF SPECIFICITY OF STRUCTURED POLYPEPTIDES | 2014 |
|
RU2674070C2 |
| MAITANZINOID DERIVATIVES WITH SELF-SPLITTING PEPTIDE LINKERS AND THEIR CONJUGATES | 2018 |
|
RU2765098C2 |
| MODULATION OF STRUCTURED PROTEINS SPECIFICITY | 2012 |
|
RU2631931C2 |
| GLYCATED PEPTIDE GLP-1 | 2009 |
|
RU2543157C2 |
